ARTICLE | Company News

ML Lab drug delivery news

May 2, 2005 7:00 AM UTC

MLB restructured to focus on its respiratory business and will reduce its headcount by 65 to about 50 employees. The respiratory business includes MLB's Clickhaler pulmonary drug delivery technology. MLB will sell or out-license Devacade opioid receptor antagonist, which is in Phase II testing to enhance the analgesic effect of morphine; CTL 102 nitroreductase gene therapy, which is in Phase II testing to treat prostate cancer; CTL 901, which is in Phase I testing to treat melanoma; and UCOE, a gene expression technology. ...